Evidence map›Paper›PMID 38911501›Full record

ArticleInternational journal of nanomedicine2024

Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.

Rosa Bellavita, Marialuisa Piccolo, Linda Leone, Maria Grazia Ferraro, Principia Dardano, Luca De Stefano, Flavia Nastri, Carlo Irace, Annarita Falanga, Stefania Galdiero

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rosa Bellavita *Department of Pharmacy, School of Medicine, University of Naples 'Federico II', Napoli, Italy.
Marialuisa Piccolo *Department of Pharmacy, School of Medicine, University of Naples 'Federico II', Napoli, Italy.
Linda LeoneDepartment of Chemical Sciences, University of Napoli "Federico II", Naples, Italy.
Maria Grazia FerraroDepartment of Pharmacy, School of Medicine, University of Naples 'Federico II', Napoli, Italy.ORCID 0000-0002-3022-1205
Principia DardanoInstitute of Applied Sciences and Intelligent Systems, Consiglio Nazionale delle Ricerche, Naples, Italy.
Luca De StefanoInstitute of Applied Sciences and Intelligent Systems, Consiglio Nazionale delle Ricerche, Naples, Italy.
Flavia NastriDepartment of Chemical Sciences, University of Napoli "Federico II", Naples, Italy.
Carlo IraceDepartment of Pharmacy, School of Medicine, University of Naples 'Federico II', Napoli, Italy.ORCID 0000-0002-5172-4573
Annarita FalangaDepartment of Agricultural Science, University of Naples "Federico II", Portici, Italy.ORCID 0000-0001-6538-8585
Stefania Galdiero *Department of Pharmacy, School of Medicine, University of Naples 'Federico II', Napoli, Italy.ORCID 0000-0002-7849-7024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The design of delivery tools that efficiently transport drugs into cells remains a major challenge in drug development for most pathological conditions. Triple-negative breast cancer (TNBC) is a very aggressive subtype of breast cancer with poor prognosis and limited effective therapeutic options. Purpose: In TNBC treatment, chemotherapy remains the milestone, and doxorubicin (Dox) represents the first-line systemic treatment; however, its non-selective distribution causes a cascade of side effects. To address these problems, we developed a delivery platform based on the self-assembly of amphiphilic peptides carrying several moieties on their surfaces, aimed at targeting, enhancing penetration, and therapy. Methods: Through a single-step self-assembly process, we used amphiphilic peptides to obtain nanofibers decorated on their surfaces with the selected moieties. The surface of the nanofiber was decorated with a cell-penetrating peptide (gH625), an EGFR-targeting peptide (P22), and Dox bound to the cleavage sequence selectively recognized and cleaved by MMP-9 to obtain on-demand drug release. Detailed physicochemical and cellular analyses were performed. Results: The obtained nanofiber (NF-Dox) had a length of 250 nm and a diameter of 10 nm, and it was stable under dilution, ionic strength, and different pH environments. The biological results showed that the presence of gH625 favored the complete internalization of NF-Dox after 1h in MDA-MB 231 cells, mainly through a translocation mechanism. Interestingly, we observed the absence of toxicity of the carrier (NF) on both healthy cells such as HaCaT and TNBC cancer lines, while a similar antiproliferative effect was observed on TNBC cells after the treatment with the free-Dox at 50 µM and NF-Dox carrying 7.5 µM of Dox. Discussion: We envision that this platform is extremely versatile and can be used to efficiently carry and deliver diverse moieties. The knowledge acquired from this study will provide important guidelines for applications in basic research and biomedicine.

Indexed as

DoxorubicinDrug Delivery SystemsNanofibersTriple Negative Breast NeoplasmsAntibiotics, AntineoplasticCell Line, TumorCell-Penetrating PeptidesCell SurvivalDrug CarriersDrug LiberationErbB ReceptorsFemaleHumansMatrix Metalloproteinase 9PeptidesAntibiotics, AntineoplasticCell-Penetrating PeptidesDoxorubicinDrug CarriersErbB ReceptorsMatrix Metalloproteinase 9Peptidesdoxorubicinnanofiberon-demand strategyself-assembling peptidestriple negative breast cancer

Identifiers

PMID38911501
PMCPMC11193445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.